germany-flag-flying-german-breeze-flag-pole-waving-1398668

Roche, Bayer and more speak out against German pricing cap plans

November 14, 2016
Sales and Marketing Bayer, Germany, Roche

A number of major drug manufacturers have spoken out against German government plans to cap prescription drug pricing in the …

richard_cm_jones

Mereo BioPharma appoint Richard Jones as CFO

November 14, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mereo BioPharma

Mereo BioPharma, a UK-based biopharmaceutical company, has announced that Richard CM Jones has been appointed chief financial officer of the …

Experimental Novartis leukaemia and mastocytosis drug gets FDA Priority Review

November 14, 2016
Research and Development, Sales and Marketing FDA, Novartis, acute myeloid leukaemia

The US FDA has granted Priority Review status to Novartis’ experimental drug PKC412 (midostaurin) as a treatment for advanced systemic …

Pfizer’s Celebrex found to be safe on hearts after 10-year clinical study

November 14, 2016
Medical Communications, Sales and Marketing Pfizer, celebrex, ibuprofen, naproxen

Pfizer’s drug, Celebrex, has been vindicated as of equivalent safety, or better, than ibuprofen and naproxen, after a 10-year study. …

gsk_wall

GSK emerges top of the pile for improving access to medicine

November 14, 2016
Medical Communications, Sales and Marketing Access to Medicine Index, GSK, market access, pricing

GlaxoSmithKline, the British drugmaker, has topped the overall ranking of the Access to Medicine Index, which ranks 20 top pharmaceutical …

top_ten_1

Top Ten articles in the Pharma Industry this week

November 11, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing November, news, pharmaceutical, top 10, top ten, top ten stories

This week has seen pharmaceutical companies defending their patent protections and host of new collaboration spring up between companies. Read …

almac_building

Almac Group announces £27 million global expansion

November 11, 2016
Medical Communications, Sales and Marketing Almac Group, investment

Almac Group, a global contract pharmaceutical development and manufacturing organisation, has announced that it will spend £27 million in a …

bionical

Bionical adds Emas Pharma in strategic acquisition

November 11, 2016
Medical Communications, Sales and Marketing Bionical, Emas pharma, acquistion

Bionical, an integrated outsourced specialist to the pharmaceutical, biotechnology and public health industry, has announced the acquisition of Emas Pharma. …

alexion_solirispackaging

Alexion begins internal probe into sales practices

November 11, 2016
Medical Communications Alexion, sales practices

Alexion Pharmaceuticals released a statement that it was to begin conducting an internal investigation into sales practices for Soliris (eculizumb) …

california

Proposition 61 defeated to allay changes on drug pricing

November 11, 2016
Medical Communications Bernie Sanders, Drug pricing, Proposition 61, california

Another major piece of voting news emerged on 9 November, with Proposition 61 voted down by Californian residents, with the …

ex-roche_guy

Former Roche CEO joins Arix Bioscience as senior independent director

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Arix Bioscience, a Britain-based healthcare and life science company, appointed Franz Humer as a senior independent director on 31 October. …

shutterstock_157775444

Social media and mobile apps: Bringing people and clinical trials together

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

In part one, we looked at the difficulty in recruiting and retaining patients for clinical trials, and how increased communication …

Pfizer’s breast cancer drug gets EU approval

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, EU, Novartis, Pfizer, ibrance

Pfizer is celebrating the approval by the European Union of its breast cancer drug Ibrance, following a positive recommendation from …

novavax

Novavax cuts works force by a third in struggle to restructure

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost cutting, Jobs, Novavax, losses

Novavax released the news that it would cut away 30% of its workforce alongside third quarter results that revenues were …

apps_mobile

Chinese FDA releases “drug scanner” app

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chinese Food and Drug Administration, app

The China Food and Drug Administration (CFDA) has released a new app earlier this week which enables users to download …

janssen_stairs

Collaboration on new therapeutic vaccine for HIV shows promise

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Janssen, Johnson & Johnson

Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into …

Pfizer to shut two out of three manufacturing plants in UK

November 9, 2016
Manufacturing and Production, Research and Development Pfizer, UK, manufacturing, production, sites

Pfizer has announced that it will close two of the three manufacturing plants it still holds in the UK. The …

amgen_hq

NICE turns down Amgen’s multiple myeloma drug

November 9, 2016
Research and Development, Sales and Marketing Amgen, Kyprolis, NICE

Amgen has seen its drug Kyprolis (carfilzomib) rejected by NICE for its routine use in the treatment of multiple myeloma …

valeant

Valeant’s tough year gets worse with Q3 loss of $1.22 billion

November 9, 2016
Research and Development Q3, Valeant, loss

It’s easy to say that Valeant hasn’t had a great year so far. Unfortunately for those concerned, the outlook for …

The Gateway to Local Adoption Series

Latest content